|
Dual synchronous primary cancers in healthy women: a case study and review article
|
Abdolali Shahrasbi1    , Fatemeh Norouzi Farsangi2 |
1- Oncology Ward, Bouali Hospital, Tehran medical sciences, Islamic Azad University, Tehran, Iran , alishahrasbi63@gmail.com
2- Oncology Ward, Bouali Hospital, Tehran medical sciences, Islamic Azad University, Tehran, Iran |
|
|
Abstract: (312 Views) |
Background: The prevalence of multiple synchronous primary cancers has increased in recent decades. The development of simultaneous multiple primary cancers in a patient may depend on hereditary, environmental, iatrogenic factors, or unknown factors. The detailed clinical history of these patients, reviewing the primary pathology reports, and the impact of immunohistochemical diagnostic methods on the planning and treatment process for these patients are the main objectives of our report.
Case presentation: in this article, we present two cases of dual primary cancers. The first case is a 46-year-old healthy woman with no significant past medical or family history of cancer and no history of using immunosuppressive drugs, who presented with advanced metastatic breast and lung cancers with sudden-onset neurological deficits. The second case is a 52-year-old healthy woman with no history of intervening factors and simultaneous locally advanced breast cancer and early-stage thyroid cancer, presenting with a large mass in her right breast and axilla.
Conclusion: Sampling from simultaneous masses in different tissues in a patient with a cancer diagnosis can play an important role in identifying multiple primary cancers. Moreover, newer techniques such as IHC have definitively proven the diagnosis of multiple primary cancers in individuals and serve as a reliable method for selecting the best and most optimal therapeutic approach for these patients s |
|
| Keywords: Synchronous multiple primary cancers, Immunohistochemistry, IHC, Treatment, Case report |
|
|
Full-Text [PDF 745 kb]
(99 Downloads)
|
Semi-pilot: Case Report |
Subject:
Oncology
Received: 2024/12/31 | Accepted: 2025/02/22 | Published: 2025/03/30
|
|
|
|
|
|
|
| References |
1. Jena A, Patnayak R, Lakshmi AY, Manilal B, Reddy MK. Multiple primary cancers: An enigma. South Asian J Cancer 2016;5:29-32. [ DOI:10.4103/2278-330X.179698] 2. Borja NA, Silva-Smith R, Calfa C, Sussman DA, Tekin M. Triple Primary Cancers: An Analysis of Genetic and Environmental Factors. Cancer Prev Res (Phila) 2024;17:209-215. [ DOI:10.1158/1940-6207.CAPR-23-0395] 3. Du Y, Duan Y, Zhang L, Gu Z, Zheng X, Li Z, Wang C. A Female With Synchronous Multiple Primary Malignant Tumors in the Esophagogastric Junction, Duodenum and Pancreas: Case Report and Review of the Literature. Front Oncol 2022;12:890587. [ DOI:10.3389/fonc.2022.890587] 4. Pan SY, Huang CP, Chen WC. Synchronous/MetachronousMultiple Primary Malignancies: Review of Associated Risk Factors. Diagnostics (Basel) 2022;12:1940. [ DOI:10.3390/diagnostics12081940] 5. Coyte A, Morrison DS, McLoone P. Second primary cancer risk-the impact of applying different definitions of multiple primaries: Results from a retrospective population-based cancer registry study. BMC Cancer 2014;14:272. [ DOI:10.1186/1471-2407-14-272] 6. Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, et al. Multiple primary tumours: Challenges and approaches, a review. ESMO Open 2017;2:e000172. [ DOI:10.1136/esmoopen-2017-000172] 7. Buiatti E, Crocetti E, Acciai S, Gafà L, Falcini F, MilandriC, et al. Incidence of second primary cancers in three Italian population-based cancer registries. Eur J Cancer 1997;33:1829-1834. [ DOI:10.1016/S0959-8049(97)00173-1] 8. Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Grande E, et al. Multiple tumours in survival estimates. Eur J Cancer 2009;45:1080-1094. [ DOI:10.1016/j.ejca.2008.11.030] 9. Lv C, Fang W, Wu N, Jiao W, Xu S, Ma H, et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial. Lung Cancer 2023;178:151- 156. [ DOI:10.1016/j.lungcan.2023.02.011] 10. Lorange JP, Ramirez Garcia Luna J, Grou-Boileau F, Rosenzweig D, Weber MH, Akoury E. Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis. J Bone Oncol 2023;39:100470. [ DOI:10.1016/j.jbo.2023.100470] 11. Bernabé R, Liu SV, Sánchez-Gastaldo A, Alonso García M. Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab. Oncol Ther 2024;12:175-182. [ DOI:10.1007/s40487-023-00257-0] 12. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001;12:S35-41. [ DOI:10.1093/annonc/12.suppl_1.S35] 13. Jamil A, Kasi A. Lung Metastasis. [Updated 2023 Jan 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearlsPublishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553111/ 14. Liskow AS, Neugut AI, Benson M, Olsson CA, Birkhoff J, Chang CH. Multiple primary neoplasms in association with prostate cancer in black and white patients. Cancer 1987;59:380-384.
https://doi.org/10.1002/1097-0142(19870115)59:2<380::AID-CNCR2820590236>3.0.CO;2-E [ DOI:10.1002/1097-0142(19870115)59:23.0.CO;2-E] 15. Qiao B, Hsieh MC, Wu XC, Kruchko C, Sineshaw H, Wu M, et al. Multiple Primary Cancers in the United States. J Registry Manag 2020;47:60-66. 16. Moriya T, Kozuka Y, Kanomata N, Tse GM, Tan PH. The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology 2009;41:68-76. [ DOI:10.1080/00313020802563544] 17. Lee NY, Hum M, Zihara S, Wang L, Myint MK, Lim DW, et al. Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer. Hum Genomics 2023;17:66. [ DOI:10.1186/s40246-023-00518-z] 18. Savkova A, Gulyaeva L, Gerasimov A, Krasil'nikov S. Genetic Analysis of Multiple Primary Malignant Tumors in Women with Breast and Ovarian Cancer. Int J Mol Sci 2023;24:6705. [ DOI:10.3390/ijms24076705] 19. Makuuchi H, Tanaka H, Shimada H, Chino O, Nishi T, Machimura T, et al. Esophageal cancer and multiple primary cancer. Gan To Kagaku Ryoho 1997;24:1-7. [In Japanese] 20. Paran M, Shulman K, Kessel B, Dagan J. Synchronous Malignancies Identified by PET-CT Scan in Breast Cancer Patients. Rambam Maimonides Med J 2022;13:e0015. [ DOI:10.5041/RMMJ.10472] 21. Jin J, Li J, Liu Y, Shi Q, Zhang B, Ji Y, et al. Thyroid Hormone Changes Correlate to Combined Breast Cancer with Primary Thyroid Cancer. Breast Cancer (Dove Med Press) 2024;16:15-22. [ DOI:10.2147/BCTT.S442707] 22. Patrizio A, Ferrari SM, Stoppini G, Palmisano E, Elia G, Ragusa F, et al. Thyroid Metastasis from Primary Breast Cancer. J Clin Med 2023;12:2709. [ DOI:10.3390/jcm12072709] 23. Kim TY, Kim WB, Gong G, Hong SJ, Shong YK. Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy. Clin Endocrinol (Oxf) 2005;62:236-41. [ DOI:10.1111/j.1365-2265.2005.02206.x] 24. Lu M, Zhang X, Chu Q, Chen Y, Zhang P. Susceptibility Genes Associated with Multiple Primary Cancers. Cancers (Basel) 2023;15:5788. [ DOI:10.3390/cancers15245788] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
|
